A Homecoming for Paladin
For Knight Therapeutics, this acquisition is more than just a business deal—it’s a reunion. Paladin Pharma was originally co-founded by Knight’s Executive Chairman, Jonathan Ross Goodman, making this acquisition deeply personal and strategic.
“The reunion of Paladin and Knight is both financially attractive and personally gratifying,” said Goodman.
Knight, a specialty pharmaceutical powerhouse, focuses on acquiring, licensing, and commercializing innovative prescription drugs across Canada and Latin America. The integration of Paladin into Knight’s operations is expected to deliver immediate financial synergies and boost its cash flow generation.
“This transaction significantly increases the scale of our Canadian business,” said Samira Sakhia, President and CEO of Knight Therapeutics. “It adds a stable portfolio of revenue-generating pharmaceuticals, fueling our expansion in both Canada and Latin America.”
Deal Timeline and Regulatory Approvals
The acquisition is set to close by mid-2025, pending the fulfillment of customary closing conditions. While legal counsel details for Knight’s advisors at Davies Ward Phillips & Vineberg LLP were not fully disclosed, Endo Inc. was represented by Davis Polk & Wardwell LLP and Torys LLP.
As the pharmaceutical industry consolidates, Knight’s latest move marks a bold step forward, positioning the company as a dominant force in the North American market.
